Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 3Recruiting 2Not yet recruiting 2Unknown 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Endocrine 1

Conditions

Small Cell Lung Carcinoma 2Lung Neoplasms 1Intracranial Germ Cell CNS Tumor, Childhood 1Carcinoma, Neuroendocrine 1

Interventions

Etoposide 27Carboplatin 26atezolizumab 16durvalumab 12Cisplatin 10Topotecan 9Drug Therapy 9PM 01183 7pembrolizumab 5Radiotherapy 5Specimen Handling 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Irinotecan 4Injections 4Immunotherapy 4trilaciclib 3toripalimab 3Temozolomide 3Radiosurgery 3Bevacizumab 3AMG 757 3tislelizumab 2monalizumab 2irinotecan sucrosofate 2enzalutamide 2apatinib 2Platinum 2Nivolumab 2Itraconazole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Small Cell Lung Carcinoma × EC regimen × Clear all
NCT05652686 2025-09-23

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Phanes Therapeutics

Phase 1/2 Recruiting
203 enrolled
EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT06698965 2024-11-21

Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin

Shanghai Chest Hospital

Phase 2 Recruiting
52 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡